Table 2.
Major Targeted Cancer Therapies
| Target | Disease | Drug | Clinical Development Status |
|---|---|---|---|
| PML-RAR-α | PML | Tretinoin | Approved |
| Bcr/abl | CML | Imatinib | Approved |
| Dasatinib | Approved | ||
| c-Kit | GIST PDGF-α | Imatinib | Approved |
| Flt-3 | AML | Semaxanib, midostaurin, tandutinib | Early-stage clinical trials |
| EGFR | NSCLC | Gefitinib | Approved/withdrawn |
| NSCLC and pancreatic cancer | Erlotinib | Approved | |
| Antiangiogenesis | MDS | Lenolidamide | Approved |
| Other major antiangiogenesis | Bevacizumab | Approved | |
| Thalidomide | Approved | ||
| Sunitinib | Approved | ||
| Sorafenib | Approved | ||
| Proteasome | MM | Bortezomib | Approved |
| HER2 | Breast cancer | Trastuzumab | Approved |
| Lapatinib | Approved | ||
| BRAF (V600E mutation) | Vemurafenib | Approved | |
| EML4-ALK translocation | Crizotinib | Approved |
Abbreviations: AML, acute myeloid leukemia; CML, chronic myeloid leukemia; EGFR, epidermal growth factor receptor; GIST, GI stromal tumor; HER2, human epidermal growth factor receptor 2; MDS, myelodysplastic syndrome; MM, multiple myeloma; NSCLC, non–small-cell lung cancer; PDGF-α, platelet-derived growth factor alpha; PML, promyelocytic leukemia; RAR-α, retinoic acid receptor alpha.